Humacyte Inc
General ticker "HUMA" information:
- Sector: Health Care
- Industry: Biotechnology
- Capitalization: $509.2M
Humacyte Inc follows the US Stock Market performance with the rate: 31.9%.
Estimated limits based on current volatility of 14.5%: low 3.87$, high 5.18$
Factors to consider:
- Earnings for 9 months up through Q3 are below our estimates
Stock Forecast*
* forecast is subjective and experimental, should not be used for any investment decisions
Long term estimates were made for the period from 2023-12-31 to 2025-12-30
- 2023-12-31 to 2024-12-30 estimated range: [1.82$, 4.40$]
- 2024-12-30 to 2025-12-30 estimated range: [2.14$, 4.91$]
Financial Metrics affecting the HUMA estimates:
- Negative: Non-GAAP EPS, $ of -0.93 <= 0.10
- Negative: Operating profit margin, % of -100 <= 1.03
- Negative: negative Net income
- Negative: Operating cash flow per share per price, % of -20.30 <= 2.35
- Negative: Industry operating profit margin (median), % of -98.30 <= 2.14
Short-term HUMA quotes
Long-term HUMA plot with estimates
Financial data
YTD | 2021-12-31 | 2022-12-31 | 2023-12-31 |
---|---|---|---|
Operating Revenue | $1.26MM | $1.56MM | $0.00MM |
Operating Expenses | $82.47MM | $86.14MM | $100.05MM |
Operating Income | $-81.21MM | $-84.58MM | $-100.05MM |
Non-Operating Income | $54.73MM | $72.61MM | $-10.73MM |
Interest Expense | $4.35MM | $6.20MM | $1.13MM |
R&D Expense | $61.34MM | $63.26MM | $76.55MM |
Income(Loss) | $-26.48MM | $-11.96MM | $-110.78MM |
Profit(Loss) | $-26.48MM | $-11.96MM | $-110.78MM |
Stockholders Equity | $122.17MM | $116.93MM | $13.55MM |
Inventory | $0.00MM | $0.03MM | $0.00MM |
Assets | $286.53MM | $204.30MM | $128.22MM |
Operating Cash Flow | $-81.19MM | $-71.13MM | $-73.31MM |
Capital expenditure | $0.22MM | $1.05MM | $2.28MM |
Investing Cash Flow | $-8.22MM | $4.84MM | $-0.17MM |
Financing Cash Flow | $266.98MM | $-1.45MM | $4.51MM |
Earnings Per Share* | $-0.94 | $-0.62 | $-1.07 |
* EPS are Split Adjusted, recent splits may be reflected with a delay.